FIERCELY
FOCUSED

on the development of novel
treatments for patients with
B-cell malignancies and
autoimmune diseases.

Learn
about us

Explore our
pipeline

investor
Information

Read our
publications

Latest News

TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib

NEW YORK , July 08, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of preclinical data describing the unique immunomodulatory effects of umbralisib, the Company’s investigational oral once-daily dual inhibitor of PI3K-delta and CK1-epsilon, in Blood

Read More >

2 Gansevoort Street, 9th Floor
New York, NY 10014

Email Us (212) 554-4484